Abstract-Some small molecular weight peptides possess potent vasoactive properties. Herein we have identified the laminin nonapeptide (LNP) CDPGYIGSR as a novel vasoconstrictive agent. Isometric force measurements revealed that LNP induced vasoconstriction in small and large murine arteries in a dose-dependent fashion; LNP also increased vascular tone in human mammary arteries. The vasoactive response was specific for the nonapeptide, because neither scrambled nor very similar peptide sequences modulated vascular tone. As an underlying mechanism we found in [Ca 2ϩ ] i imaging experiments that the nonapeptide induced transmembrane [Ca 2ϩ ] i influx in vascular smooth muscle cells. Patch clamp experiments showed that LNP activated nonselective cation channels, causing depolarization of the membrane potential and opening of L-type Ca 2ϩ channels. The functional effect of LNP was also assessed with catheter measurements in mice in vivo and confirmed vasoconstriction. This effect was restricted to the systemic circulation, because measurements with the perfused lung system demonstrated that LNP did not alter vascular tone in pulmonary arteries. Thus, LNP is a vasoconstrictor in mouse and human arteries, and its vasoactivity is restricted to the systemic vasculature. (Hypertension. 2012;59:1256-1262.) • Online Data Supplement Key Words: cell signaling Ⅲ ion channels Ⅲ peptides Ⅲ smooth muscle Ⅲ vasoconstriction T he identification of vasoactive substances is of high interest for a better molecular understanding of the regulation of vascular tone and for the design of novel therapeutic agents. Different small peptides (eg, endothelin, angiotensin II, and bradykinin) have been found to exert potent vasomodulatory functions.1,2 Most of these peptides are derived from larger molecules that have no effect on vascular tone and are processed to vasoactive molecules via proteolytic cleavage. These can either have vasoconstrictive (endothelin or vasopressin) or vasorelaxant (bradykinin) properties and also exert other cell biological functions; for example, endothelin and angiotensin II stimulate proliferation of smooth muscle cells.
3The 9 amino acid peptide CDPGYIGSR, which is part of the LEb domain in the 1 chain of laminin, has been shown to affect vascular growth. 4 In addition, the peptide was also suggested to bind to the 67-kDa laminin receptor, 5 resulting in the inhibition of metastases formation. 6 The minimum sequence necessary for these effects was identified as the laminin pentapeptide YIGSR that also promoted vascular tube formation 5,7 and could inhibit shear stress-induced increase in endothelial NO expression. 8 In addition, laminin was also reported to modulate L-type Ca 2ϩ channels. 9 Because laminin and its 1 chain were shown to be in close contact with the endothelium and the smooth muscle layer of vessels 10 and a laminin fragment containing laminin nonapeptide (LNP) was found to be increased in blood of patients experiencing diabetes mellitus, 11 we explored whether LNP has direct impact on va...